GLAUKOS Corp (GKOS) Stock
7 of the hedge funds AlphaScala tracks reported GKOS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $220.96M. Company insiders reported 0 open-market buys and 22 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own GKOS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.58M | $220.96M | +35% |
| Citadel Ken Griffin | 1.39M | $194.27M | -4% |
| Marshall Wace | 315K | $44.00M | +823% |
| Renaissance Technologies Jim Simons (founder) | 147K | $20.57M | +24% |
| Point72 Steve Cohen | 138K | $19.33M | +36% |
| D.E. Shaw David Shaw | 57K | $7.99M | -77% |
| Bridgewater Associates Ray Dalio | 3K | $462.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are GLAUKOS Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 888 | $146K |
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 327 | $54K |
| Oct 5, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 312 | $52K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 167 | $25K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 136 | $21K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 229 | $35K |
| Sep 25, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 1.1K | $168K |
| Sep 16, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 103 | $17K |
| Sep 16, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 345 | $57K |
| Sep 16, 26 | Navratil Tomas | CHIEF DEVELOPMENT OFFICER | SELL | 191 | $32K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →GKOS price chart
Powered by TradingViewWhat does GLAUKOS Corp do?
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.